Table 4 Description of the true and false positive and true false negative measurements

Number of patients (n)

99

Total number of visits (n)

381

76

48

244

13

Age (years)

median (IQR)

21 (11–38)

23 (10–35)

36 (23–57)

(p = 0.240)

18 (9–30)

17 (15–58)

(p = 0.531)

BMI (kg/m2), mean (±SD)

22.53 (±5.75)

21.96 (±4.56)

28.16 (±7.25)

(p < 0.001)*

21.80 (±5.60)

23.77 (±0.34)

(p = 0.875)

CRP values mg/L, median (IQR)

2.00 (0.40–9.00)

29 (12.00–54.00)

10 (7.00–11.00)

0.70 (0.30–1.80)

2.70 (1.40–4.25)

SAA values mg/L, median (IQR)

1.00 (0.50–4.50)

43.50 (15.75–109.50)

2.00 (1.00–4.00)

1.00 (1.00–1.00)

10.00 (7.00–39.00)

Visits with medication usage, n (%)

Colchicine 166 (43.6%),

Colchicine 27 (35.5%),

Colchicine 20 (41.7%),

Colchicine 115 (47.1%),

Colchicine 4 (30.8%),

Canakinumab 67 (17.6%),

Canakinumab 8 (10.5%),

Canakinumab 9 (18.8%),

Canakinumab 49 (20.1%),

Canakinumab 1 (7.7%),

Anakinra 59 (15.5%),

Anakinra 16 (21.1%),

Anakinra 8 (16.6%),

Anakinra 33 (13.5%),

Anakinra 2 (15.4%),

Prednisone 28 (7.3%),

Prednisone 11 (14.5%),

Prednisone 1 (2.1%),

Prednisone 13 (5.3%),

Prednisone 3 (23.1%),

Tocilizumab 6 (1.6%),

Tocilizumab 0, (0%)

Tocilizumab 0, (0%)

Tocilizumab 6 (2.5%), (0%)

Tocilizumab 0, (0%)

Humira 3 (0.8%),

Humira 0, (0%)

Humira 0, (0%)

Humira 3 (1.2%),

Humira 0, (0%)

antibiotics 4 (1%),

antibiotics 1 (1.3%),

antibiotics 2 (4.2%),

antibiotics 1 (0.4%),

antibiotics 0, (0%)

no medication 48 (12.6%)

no medication 13 (17.1%)

no medication 0 (0%)

no medication 24 (9.8%)

no medication 4 (30.8%)

Conclusion of visit based on expert opinion and ADAI, n (%)

Flare up AID 40 (10%),

Flare up AID 22 (28.9%),

Flare up AID 7 (15%),

Flare up AID 11 (4.5%),

remission 13 (100%)

remission 320 (84%),

remission 45 (59.2%),

remission 37 (77%),

Remission 225 (92.6%),

infection 8 (2%)

infection 4 (5.3%),

infection 2 (4%),

Infection 2 (0.8%),

unknown 13 (3%)

Unknown 5 (6.6%)

Unknown 2 (4%)

unknown 6 (2.5%)